Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Common Stock Repurchased

Cash spent buying back the company's own shares.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Common Stock Repurchased · Q2 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q2 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 common stock repurchased of $0 is the largest of the 9 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 0.0% of revenue for OTLK, versus a peer median of 0.0%.
OTLK Competitors Peer median
Common Stock Repurchased for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 ———
CUECue Biopharma, Inc.LTM Mar 2026$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
EQEquillium, Inc.LTM Mar 2026$0 ———
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$0 +100.0%—0.0%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
Peer median (excluding OTLK) $0+100.0%—0.0%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
Deferred Income Tax498.49K0000
Stock-Based Compensation4.89M7.71M5.55M5.39M8.9M
Change in Working Capital(7.08M)(1.68M)4.75M(3.02M)4.86M
Accounts Receivables0000(1.49M)
Inventory0000(3.34M)
Accounts Payables(198.47K)1.3M3.08M1.39M1.67M
Other Working Capital(6.88M)(2.98M)1.67M(4.41M)8.02M
Other Non-Cash Items341.55K3.15M5.66M4.09M1.58T
Operating Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)
Capital Expenditures0000(3)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment6.31M(2.32M)19.77M(4.27K)(3.04M)
Common Stock Issued46.3M62.31M30.02M60.33M48.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M(394.15K)(823.89K)044.98T
Financing Cash Flow56.19M59.59M48.97M60.33M44.98M
Effect of Forex Changes00000
Net Change in Cash1.94M2.92M6M(8.46M)(6.84M)
Free Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.